Bridged nucleic acids reloaded
- Autores
- Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.
Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos - Materia
-
ANTIBIOTIC RESISTANCE
ANTISENSE
BRIDGED NUCLEIC ACIDS
CAS9
CRISPR
HEMATOLOGIC MALIGNANCIES
HYPERCHOLESTEROLEMIA
LOCKED NUCLEIC ACIDS
MYOTONIC DYSTROPHY
OLIGONUCLEOTIDES - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/151385
Ver los metadatos del registro completo
id |
CONICETDig_ca278490f124df8367587d5b4d95615d |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/151385 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Bridged nucleic acids reloadedSoler Bistue, Alfonso J. C.Zorreguieta, ÁngelesTolmasky, Marcelo E.ANTIBIOTIC RESISTANCEANTISENSEBRIDGED NUCLEIC ACIDSCAS9CRISPRHEMATOLOGIC MALIGNANCIESHYPERCHOLESTEROLEMIALOCKED NUCLEIC ACIDSMYOTONIC DYSTROPHYOLIGONUCLEOTIDEShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Tolmasky, Marcelo E.. California State University; Estados UnidosMolecular Diversity Preservation International2019-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/151385Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-171420-3049CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/24/12/2297info:eu-repo/semantics/altIdentifier/doi/10.3390/molecules24122297info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:37:29Zoai:ri.conicet.gov.ar:11336/151385instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:37:29.689CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Bridged nucleic acids reloaded |
title |
Bridged nucleic acids reloaded |
spellingShingle |
Bridged nucleic acids reloaded Soler Bistue, Alfonso J. C. ANTIBIOTIC RESISTANCE ANTISENSE BRIDGED NUCLEIC ACIDS CAS9 CRISPR HEMATOLOGIC MALIGNANCIES HYPERCHOLESTEROLEMIA LOCKED NUCLEIC ACIDS MYOTONIC DYSTROPHY OLIGONUCLEOTIDES |
title_short |
Bridged nucleic acids reloaded |
title_full |
Bridged nucleic acids reloaded |
title_fullStr |
Bridged nucleic acids reloaded |
title_full_unstemmed |
Bridged nucleic acids reloaded |
title_sort |
Bridged nucleic acids reloaded |
dc.creator.none.fl_str_mv |
Soler Bistue, Alfonso J. C. Zorreguieta, Ángeles Tolmasky, Marcelo E. |
author |
Soler Bistue, Alfonso J. C. |
author_facet |
Soler Bistue, Alfonso J. C. Zorreguieta, Ángeles Tolmasky, Marcelo E. |
author_role |
author |
author2 |
Zorreguieta, Ángeles Tolmasky, Marcelo E. |
author2_role |
author author |
dc.subject.none.fl_str_mv |
ANTIBIOTIC RESISTANCE ANTISENSE BRIDGED NUCLEIC ACIDS CAS9 CRISPR HEMATOLOGIC MALIGNANCIES HYPERCHOLESTEROLEMIA LOCKED NUCLEIC ACIDS MYOTONIC DYSTROPHY OLIGONUCLEOTIDES |
topic |
ANTIBIOTIC RESISTANCE ANTISENSE BRIDGED NUCLEIC ACIDS CAS9 CRISPR HEMATOLOGIC MALIGNANCIES HYPERCHOLESTEROLEMIA LOCKED NUCLEIC ACIDS MYOTONIC DYSTROPHY OLIGONUCLEOTIDES |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications. Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos |
description |
Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/151385 Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-17 1420-3049 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/151385 |
identifier_str_mv |
Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-17 1420-3049 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/24/12/2297 info:eu-repo/semantics/altIdentifier/doi/10.3390/molecules24122297 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613180868788224 |
score |
13.070432 |